B0382 - Barriers to Inflammatory Bowel Disease (IBD) Care in a Racially and Ethnically Diverse Population: Patient Survey and Chart Review Study

Shamita Shah, MD¹, Edmond K. Kabagambe, PhD, MS, MBA¹, Alicia Shillington, PhD, MPH², Aarti A. Patel, PharmD, MBA³, Joseph A. Capelouto, MHA¹, Kathleen L. Deering, PharmD², Ardem Elmayan, MPH¹, Sheena Babin, PharmD¹, Brandon LaChappelle, MPH², Julia Liu, MD^4
1Ochsner Health, New Orleans, LA; ²EPI-Q, Inc, Oak Brook, IL; ³Janssen Scientific Affairs, LLC, Titusville, NJ; ⁴Morehouse School of Medicine, Atlanta, GA

Introduction: Data on IBD access to care and patient outcomes in Black/Indigenous/People of Color or Hispanic (BIOPOC/H) populations is limited. Previous studies suggest lower access to IBD specialists in Black and Hispanics may lead to worse outcomes. This study evaluated care barriers, clinical disease status and outcomes among a diverse population of White/Non-Hispanics (W/NH) and BIPOC/H patients with IBD treated at a large health system in in the US.

Methods: An anonymous online survey was created with input from a diverse panel of patients with IBD and sent once to adult patients with IBD treated in the health system between Aug 2019 - Dec 2021. The study protocol was approved by the Institutional Review Board. Arbitrary identifiers linked respondents to deidentified electronic medical record (EMR) data. Collected were demographics, symptoms, care access via the Consumer Assessment of Healthcare Providers and Systems and Barriers to Care surveys, health-related quality of life (HRQOL) via the Short Inflammatory Bowel Disease Questionnaire, the Medication Adherence Rating Scale-4, and the Beliefs about Medicines Questionnaire. EMR data examined healthcare resource utilization. Analyses compared W/NH and BIPOC/H via X² and t-tests.

Results: 171 out of 1,210 surveyed responded (14%); 103 (60%) W/NH, and 68 BIPOC/H (40%). Demographic information is shown in Table 1. BIPOC/H patients were younger and more likely to be underinsured. BIPOC/H compared to W/NH patients reported more difficulties seeing an IBD specialist (35% vs 21%; p=.04), having inadequate control of symptoms (82% vs 65%; p=.01), including more abdominal pain (58% vs 38%; p=.04) and diarrhea (70% vs 47%; p=.004). BIPOC/H patients had lower mean [SD] HRQOL scores (41 [14] vs 49 [13]; ; p< .001), reported IBD symptoms more often impacting employment (50% vs 33%; p=.029 and financial stability (53% vs 32%; p=.006). BIPOC/H patients reported more problems finding social and emotional supports to deal with IBD (64% vs 37%; p< .001). EMR data suggests BIPOC/H patients utilized Emergency Department (ED) services more often than W/NH patients in the previous 14 months (42% vs 22%; p=.004), respectively.

Discussion: BIPOC/H patients with IBD had worse clinical disease, lower HRQOL scores, less access to specialists, less social and emotional support, and used more ED services than W/NHs. Future programs to understand and address the differences in their care and outcomes are needed.



Disclosures:


Shamita Shah, MD¹, Edmond K. Kabagambe, PhD, MS, MBA¹, Alicia Shillington, PhD, MPH², Aarti A. Patel, PharmD, MBA³, Joseph A. Capelouto, MHA¹, Kathleen L. Deering, PharmD², Ardem Elmayan, MPH¹, Sheena Babin, PharmD¹, Brandon LaChappelle, MPH², Julia Liu, MD⁴. B0382 - Barriers to Inflammatory Bowel Disease (IBD) Care in a Racially and Ethnically Diverse Population: Patient Survey and Chart Review Study, ACG 2022 Annual Scientific Meeting Abstracts. Charlotte, NC: American College of Gastroenterology.